CCNE1 and chronic hepatitis B virus infection: Therapeutic targeting of Cyclin E1 via RNAi has been shown to have robust anti-fibrotic activity in mice (Bangen et al., 2017), and if this technology can be applied clinically in future, we predict that it will be most effective in those patients with chronic hepatitis B.